Sutimlimab-jome: another of the monoclonal antibodies expressed by recombinant in CHO cells to be fda approved in 2022!
Sutimlimab-jome is another of the monoclonal antibodies expressed by recombinant in CHO cells to be fda approved in 2022! Developed by Bioverativ, a Sanofi company and commercialized under the name of Enjaymo, it is a classical complement inhibitor indicated to decrease the need for red blood cell (RBC) transfusion due to hemolysis in adults with cold agglutinin disease (CAD)* The role of CHOcells in drugdiscovery , drugdevelopment and drugmanufacturing is growing very fast, offering […]